Search
Lornoxicam
go.drugbank.com/drugs/DB06725ApprovedInvestigationalLornoxicam (chlortenoxicam) is a new nonsteroidal anti-inflammatory drug (NSAID) of the oxicam class with analgesic, anti-inflammatory and antipyretic properties. Lornoxicam differs from other oxicam compounds in its potent inhibition of...
Categories: Anti-Inflammatory Agents, Non-Steroidal (Non-Selective), Analgesics, Non-NarcoticCholestyramine
go.drugbank.com/drugs/DB01432ApprovedInvestigationalCholestyramine resin is quite hydrophilic, but insoluble in water.
Categories: Non-statin Hypolipidemic Agents Indicated for HyperlipidemiaManganese gluconate
go.drugbank.com/drugs/DB11141ApprovedIt is typically obtained by reacting manganese carbonate with gluconic acid in aqueous medium and then crystallizing the product to form a slightly pink powder.
Mixtures: Super Daily No 2Dronedarone
go.drugbank.com/drugs/DB04855ApprovedInvestigational[A34604,L8699] Dronedarone is a related benzofuran compound to amiodarone but its chemical structure lacks iodine moieties which are associated with amiodarone-induced thyroid problems. … It is managed by rate control, rhythm control, prevention of thromboembolic events, and treatment of the underlying disease.
Synonyms: N-(2-butyl-3-(4-(3-(dibutylamino)propoxy)benzoyl)-5-benzofuranyl)-methanesulfonamide, N-(2-butyl-3-(p-(3-(dibutylamino)propoxy)benzoyl)-5-benzofuranyl)methanesulfonamideObinutuzumab
go.drugbank.com/drugs/DB08935ApprovedInvestigational[L54521] First approved by the FDA on February 26, 2016,[L54531] obinutuzumab is used to treat chronic lymphocytic leukemia, follicular lymphoma, and lupus nephritis.[L54521] … Obinutuzumab is a humanized anti-CD20 monoclonal antibody designed to treat B-cell malignancies.
Dacomitinib
go.drugbank.com/drugs/DB11963ApprovedInvestigationalDacomitinib, designed as (2E)-N-16-4-(piperidin-1-yl) but-2-enamide, is an oral highly selective quinazalone part of the second-generation tyrosine kinase inhibitors which are characterized by the irreversible … [A40009] Dacomitinib was developed by Pfizer Inc and approved by the FDA on September 27, 2018.
Inclisiran
go.drugbank.com/drugs/DB14901ApprovedInvestigationalBy binding to PCSK9 messenger RNA, inclisiran prevents protein translation of PCSK9, leading to decreased concentrations of PCSK9 and plasma concentrations of LDL cholesterol. … [L28178] Inclisiran was later approved by the FDA on December 22, 2021, for the treatment of heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease in adults
Categories: Non-statin Hypolipidemic Agents Indicated for HyperlipidemiaOlezarsen
go.drugbank.com/drugs/DB18728ApprovedInvestigational[A264888] Olezarsen works to reduce the plasma triglyceride levels by reducing APOC3 production. … [L52033] On December 19, 2024, olezarsen was approved by the FDA for the treatment of familial chylomicronemia syndrome.[L52028] It is also being investigated for the treatment of hyperlipidemia.
Synonyms: DNA, D(P-THIO)((2'-O-(2-METHOXYETHYL))RA-(2'-O-(2-METHOXYETHYL))RG-(2'-O-(2-METHOXYETHYL))M5RC-(2'-O-(2-METHOXYETHYL))M5RU-(2'-O-(2-METHOXYETHYL))M5RU-M5C-T-T-G-T-M5C-M5C-A-G-M5C-(2'-O-(2-METHOXYETHYL), )M5RU-(2'-O-(2-METHOXYETHYL))M5RU-(2'-O-(2-METHOXYETHCategories: Non-statin Hypolipidemic Agents Indicated for HyperlipidemiaNuvaxovid
go.drugbank.com/drugs/DB15810ApprovedInvestigational[L39534,L47386] On February 17, 2022, nuvaxovid was approved by Health Canada. … [A243789, A243794, A243799] The European Commission granted Novavax conditional marketing authorization for nuvaxovid for active immunization to prevent COVID-19 caused by SARS-CoV-2 on December 20,
Crizotinib
go.drugbank.com/drugs/DB08865ApprovedInvestigational[A250785] Crizotinib was approved by the FDA in 2011, and its use is accompanied by FDA-approved tests used to detect ALK and ROS1 rearrangements.[L42460] … [A250785] Crizotinib was the first-in-class drug used to treat ALK-positive tumors.